March 10, 2020
Constellation Pharmaceuticals
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results
March 10, 2020
KALA BIO
Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock
March 10, 2020
KALA BIO
Kala Pharmaceuticals Announces Pricing of Public Offering of 16,000,000 Shares of Common Stock
March 09, 2020
KALA BIO
Kala Pharmaceuticals Announces Statistically Significant Results for Primary and Key Secondary Endpoints in STRIDE 3 Clinical Trial Evaluating EYSUVIS™ for Signs and Symptoms of Dry Eye Disease
March 09, 2020
Revolution Medicines
New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute